Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1

Priya Ragunathan; Thomas Dick; Gerhard Grüber

doi:10.1128/aac.00018-22

Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1

Priya Ragunathan, Thomas Dick, Gerhard Grüber^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

New drug targets and molecules with bactericidal activity are needed against the respiratory mycobacterial pathogen Mycobacterium abscessus. Employing a lead repurposing strategy, the antituberculosis compound GaMF1 was tested against M. abscessus. Whole-cell and ATP synthesis assays demonstrated that GaMF1 inhibits growth and kills M. abscessus by targeting the F-ATP synthase. GaMF1's anti- M. abscessus activity increased in combination with clofazimine, rifabutin, or amikacin. The study expands the repertoire of anti-M. abscessus compounds targeting oxidative phosphorylation.

Original language	English
Journal	Antimicrobial Agents and Chemotherapy
Volume	66
Issue number	5
DOIs	https://doi.org/10.1128/aac.00018-22
Publication status	Published - May 2022
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2022 American Society for Microbiology.

ASJC Scopus Subject Areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Keywords

bioenergetics
FATP synthase,g subunit inhibitor
multidrug resistance
Mycobacterium abscessus
nontuberculous mycobacteria

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1128/aac.00018-22

Cite this

@article{b7e596e9356e46a6bec30142413f029b,

title = "Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1",

abstract = "New drug targets and molecules with bactericidal activity are needed against the respiratory mycobacterial pathogen Mycobacterium abscessus. Employing a lead repurposing strategy, the antituberculosis compound GaMF1 was tested against M. abscessus. Whole-cell and ATP synthesis assays demonstrated that GaMF1 inhibits growth and kills M. abscessus by targeting the F-ATP synthase. GaMF1's anti- M. abscessus activity increased in combination with clofazimine, rifabutin, or amikacin. The study expands the repertoire of anti-M. abscessus compounds targeting oxidative phosphorylation.",

keywords = "bioenergetics, FATP synthase,g subunit inhibitor, multidrug resistance, Mycobacterium abscessus, nontuberculous mycobacteria",

author = "Priya Ragunathan and Thomas Dick and Gerhard Gr{\"u}ber",

note = "Publisher Copyright: {\textcopyright} 2022 American Society for Microbiology.",

year = "2022",

month = may,

doi = "10.1128/aac.00018-22",

language = "English",

volume = "66",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "5",

}

TY - JOUR

T1 - Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1

AU - Ragunathan, Priya

AU - Dick, Thomas

AU - Grüber, Gerhard

PY - 2022/5

Y1 - 2022/5

N2 - New drug targets and molecules with bactericidal activity are needed against the respiratory mycobacterial pathogen Mycobacterium abscessus. Employing a lead repurposing strategy, the antituberculosis compound GaMF1 was tested against M. abscessus. Whole-cell and ATP synthesis assays demonstrated that GaMF1 inhibits growth and kills M. abscessus by targeting the F-ATP synthase. GaMF1's anti- M. abscessus activity increased in combination with clofazimine, rifabutin, or amikacin. The study expands the repertoire of anti-M. abscessus compounds targeting oxidative phosphorylation.

AB - New drug targets and molecules with bactericidal activity are needed against the respiratory mycobacterial pathogen Mycobacterium abscessus. Employing a lead repurposing strategy, the antituberculosis compound GaMF1 was tested against M. abscessus. Whole-cell and ATP synthesis assays demonstrated that GaMF1 inhibits growth and kills M. abscessus by targeting the F-ATP synthase. GaMF1's anti- M. abscessus activity increased in combination with clofazimine, rifabutin, or amikacin. The study expands the repertoire of anti-M. abscessus compounds targeting oxidative phosphorylation.

KW - bioenergetics

KW - FATP synthase,g subunit inhibitor

KW - multidrug resistance

KW - Mycobacterium abscessus

KW - nontuberculous mycobacteria

UR - http://www.scopus.com/inward/record.url?scp=85130350440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130350440&partnerID=8YFLogxK

U2 - 10.1128/aac.00018-22

DO - 10.1128/aac.00018-22

M3 - Article

C2 - 35481752

AN - SCOPUS:85130350440

SN - 0066-4804

VL - 66

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 5

ER -

Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1

Abstract

Bibliographical note

ASJC Scopus Subject Areas

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this